The direct thrombin inhibitor ximelagatran/melagatran: A systematic review on clinical applications and an evidence based assessment of risk benefit profile

Expert Opinion on Drug Safety

Volumn 6, Issue 4, 2007, Pages 397-406

  Testa, Luca ^a   Bhindi, Ravinai ^a   Agostoni, Pierfrancesco ^b   Abbate, Antonio ^c   Biondi Zoccai, Guiseppe G L ^d   Van Gaal, William J ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b MIDDELHEIM HOSPITAL   (Belgium)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

Anticoagulants; Melagatran; Meta analysis; Thrombosis; Ximelagatran

Indexed keywords

DALTEPARIN; ENOXAPARIN; MELAGATRAN; PLACEBO; WARFARIN; XIMELAGATRAN; ANTICOAGULANT AGENT; ANTITHROMBIN; AZETIDINE DERIVATIVE; BENZYLAMINE DERIVATIVE; THROMBIN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEMARTHROSIS; HEMOPERICARDIUM; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTRAOCULAR HEMORRHAGE; LIVER TOXICITY; LUNG EMBOLISM; META ANALYSIS; PHLEBOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RETROPERITONEAL HEMORRHAGE; REVIEW; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM; ANIMAL; DRUG ANTAGONISM; EVIDENCE BASED MEDICINE; METHODOLOGY; RISK ASSESSMENT;

ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; AZETIDINES; BENZYLAMINES; EVIDENCE-BASED MEDICINE; HUMANS; RISK ASSESSMENT; THROMBIN;

EID: 34548473336     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.6.4.397     Document Type: Review

References (25)

1. HIRSH J, FUSTER V, ANSELL J, HALPERIN JL: American heart association/ American college of cardiology foundation guide to Warfarin therapy. Circulation (2003) 107:1692-1711.
2. HIRSH J, DALEN JE, ANDERSON DR et al.: Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (1998) 114:S445-S469.
3. AGENO W, CROTTI S, TURPIE AG: The safety of antithrombotic therapy during pregnancy. Expert Opin. Drug Saf. (2004) 3:113-118.
4. HOLZHEIMER RG: Low-molecular-weight heparin (LMWH) in the treatment of thrombosis. Eur. J. Med. Res. (2004) 9:225-239.
5. BAUER KA: New anticoagulants: anti IIa vs anti Xa-Is one better? J. Thromb. Thrombolysis (2006) 21:67-72.
6. DI NISIO M, MIDDLEDORP S, BULLER HR: Direct thrombin inhibitors. N. Engl. J. Med. (2005) 353:1028-1040.
7. BERGSRUD EA, GANDHI PJ: A review of the clinical uses of Ximelagatran in thrombosis syndromes. J. Thromb. Thrombolysis (2003) 16:175-188.
8. BIONDI ZOCCAI GG, AGOSTONI P, ABBATE A, TESTA L, BURZOTTA F: A simple hint to improve Robinson and Dickersin's highly sensitive PubMed search strategy for controlled clinical trials. Int. J. Epidemiol. (2005) 34:224-225.
9. CLARKE M, OXMAN AD: Cochrane Reviewers' Handbook 4.1.3. In: The Cochrane Library, Issue 3. Update Software, Oxford, UK (2001).
10. HEIT JA, COLWELL CW, FRANCIS CW et al.: AstraZeneca Arthroplasty Study Group. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a Phase II dose-finding study. Arch. Intern. Med. (2001) 161:2215-2221.
11. ERIKSSON BI, ARFWIDSSON AC, FRISON L et al.: A dose-ranging study of oral direct thrombin inhibitor ximelagatran, and its subcutaneous form melagatran, compared with dalteparin in the prophylaxis of thromboembolism after total hip or knee replacement: METHRO I. MElagatran for Thrombin inhibition in Orthopaedic surgery. Thromb. Haemost. (2002) 87:231-237.
12. ERIKSSON BI, BERGQVIST D, KALEBO P et al.: Melagatran for thrombin inhibition in orthopaedic surgery. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomized trial. Lancet (2002) 360:1441-1447.
13. FRANCIS CW, DAVIDSON BL, BERKOWITZ SD et al.: Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. Ann. Intern. Med. (2002) 137:648-655.
14. COLWELL CW, BERKOWITZ SD, DAVIDSON BL et al.: Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, doubleblind study. J. Thrombo. Haemost. (2003) 1:2119-2130.
15. ERIKSSON BI, AGNELLI G, COHEN AT et al.; METHRO III STUDY GROUP: Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement: The METHRO III study. Thromb. Haemost. (2003) 89:288-296.
16. ERIKSSON BI, AGENLLI G, COHEN AT et al.; on behalf of the EXPRESS STUDY GROUP: The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J. Thromb. Haemost. (2003) 1:2490-2496.
17. FRANCIS CW, BERKOWITZ SD, COMP PC et al.; EXULT A STUDY GROUP: Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N. Engl. J. Med. (2003) 349:1703-1712.
18. ERIKSSON H, WAHLANDER K, GUSTAFSSON D, WELIN LT, FRISON L, SCHULMAN S: A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J. Thrombo. Haemost. (2003) 1:41-47.
19. FIESSINGER JN, HUISMAN MV, DAVIDSON BL et al.; THRIVE TREATMENT STUDY INVESTIGATORS: Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA (2005) 293:681-689.
20. PETERSEN P, GRIND M, ADLER J: Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: SPORTIF II. J. Am. Coll. Cardiol. (2003) 41:1445-1451.
21. OLSSON SB; EXECUTIVE STEERING COMMITTEE on behalf of the SPORTIF III INVESTIGATORS: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet (2003) 362:1691-1698.
22. ALBERS GW, DIENER HC, FRISON L et al.; SPORTIF EXECUTIVE STEERING COMMITTEE FOR THE SPORTIF V INVESTIGATORS: Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA (2005) 293:690-698.
23. WALLENTIN L, WILCOX RG, WEAVER WD et al.; ESTEEM INVESTIGATORS: Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet (2003) 362:789-797.
24. SCHULMAN S, WAHLANDER K, LUNDSTROM T, CLASON SB, ERIKSSON H; THRIVE III INVESTIGATORS: Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N. Engl. J. Med. (2003) 349:1713-1721.
25. TESTA L, TROTTA G, ABBATE A, AGOSTONI P, BIONDI-ZOCCAI GG: The hurdles of warfarin and the hurdles of clinical practice. Stroke (2006) 37:2867.